Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development

ABSTRACT SARS-CoV-2 poses an ongoing threat to human health as variants continue to emerge. Several effective vaccines are available, but a diminishing number of Americans receive the updated vaccines (only 22% received the 2023 update). Public hesitancy towards vaccines and common occurrence of “br...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ariel J. Kuhn, Victor K. Outlaw, Tara C. Marcink, Zhen Yu, Megan C. Mears, Maria N. Cajimat, Dale F. Kreitler, Payton R. Cleven, Jee Ching Mook, Dennis A. Bente, Matteo Porotto, Samuel H. Gellman, Anne Moscona
Formato:	Artigo
Idioma:	Inglês
Publicado:	American Society for Microbiology 2025-03-01
Series:	Journal of Virology
Assuntos:	SARS-CoV-2 lipopeptide solubility inhibitors viral fusion heptad repeats
Acceso en liña:	https://journals.asm.org/doi/10.1128/jvi.02159-24
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!